|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-6-11
|
|
pubmed:abstractText |
This report deals with an unusual case of a patient with follicular small cleaved lymphocytic lymphoma who developed Merkel-cell carcinoma soon after receiving chemoimmunotherapy with a fludarabine-containing regimen and rituximab. The presentation of the Merkel-cell carcinoma in this patient was atypical because of the absence of dermal involvement and the very rapid clinical progression. In the light of recent reports which suggest a possible link between the immunocompromised state and the development of Merkel-cell carcinoma, the atypical presentation seen in this patient may indeed imply a possible link between the therapy given and the development of Merkel-cell carcinoma. To the best of our knowledge, this is the first documentation of Merkel-cell carcinoma appearing in a patient soon after treatment with fludarabine and/or rituximab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0902-4441
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
117-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12061321-Antibodies, Monoclonal,
pubmed-meshheading:12061321-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:12061321-Antineoplastic Agents,
pubmed-meshheading:12061321-Carcinoma, Merkel Cell,
pubmed-meshheading:12061321-Humans,
pubmed-meshheading:12061321-Lymphoma, Follicular,
pubmed-meshheading:12061321-Male,
pubmed-meshheading:12061321-Middle Aged,
pubmed-meshheading:12061321-Neoplasms, Second Primary,
pubmed-meshheading:12061321-Recurrence,
pubmed-meshheading:12061321-Salvage Therapy,
pubmed-meshheading:12061321-Vidarabine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
|
|
pubmed:affiliation |
Department of Hematology, Hadassah University Hospital, Jerusalem, Israel.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
